ArticlePloS one2026
Prescription patterns of inhaler medications from 2017 to 2023: A retrospective study using Ontario administrative healthcare data.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInhalers are essential for respiratory disease management, but commonly used metered-dose inhalers (MDIs) can often be replaced, when clinically appropriate, with lower-emission alternatives such as dry powder inhalers (DPIs) or soft mist inhalers (SMIs). The COVID-19 pandemic may have influenced prescribing patterns. We aim to describe changes in inhaler prescription trends and determine whether MDI use decreased during the pandemic. METHODS AND
findingsRetrospective cohort study using Ontario's health administrative data. Individuals aged 65 and older with new inhaler prescription instances from April 1, 2017, to March 31, 2023, were included. Monthly prescription event rates by inhaler type and socioeconomic factors were modeled for pre-pandemic (April 2017-March 2020) and pandemic (April 2020-March 2023) periods using interrupted time series and Generalized Additive Models to account for autocorrelation and seasonality. 750,517 new inhaler prescriptions were made during the study period. A significant drop was observed at the pandemic's onset. MDIs were the predominant type of inhaler initially prescribed for both pre-pandemic ~77% and pandemic ~70% periods. The proportion of DPI initial prescriptions modestly increased from ~17% to ~23% and SMI initial prescriptions remained similar. Inhaler prescription rates did not significantly differ across sex, income quintiles, or rurality.
conclusionsThe COVID-19 pandemic disrupted inhaler prescribing patterns in Ontario, leading to a temporary decline in new prescriptions. Despite environmental and guideline recommendations, MDIs continued to dominate prescribing practices. These findings underscore the need for targeted interventions to align clinical practices with current guidelines and environmental sustainability goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.